Lei Zhang

Dr. Lei Zhang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2025 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
XXXiawei Xu
Xiawei Xu
SZSongchen Zhao
Songchen Zhao
YXYujiao Xie
Yujiao Xie
LZLei Zhang
Lei Zhang
YSYong Shao
Yong Shao
Aiguo WuAiguo Wu
Aiguo Wu

6 January 2025 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
\L\R\Nrongmu Luo
\R\Nrongmu Luo
GMGuannan Ma
Guannan Ma
QYQian Yu
Qian Yu
ZTZhengqin Tian
Zhengqin Tian
QMQihang Man
Qihang Man
JWJingbo Wang
Jingbo Wang
Introduction: Hypervirulent carbapenem-resistant Klebsiella pneumoniae (hv-CRKP) poses an increasing public health risk due to its high treatment difficulty and associated mortality, especially in bone marrow transplant (BMT) patients. The emergence of strains with multiple resistance mechanisms further complicates the management of these infections.Methods: We isolated and characterized a novel ST11-KL64 hv-CRKP strain from a pediatric bone marrow transplantation patient. Antimicrobial susceptibility testing was performed to determine resistance patterns. Comprehensive genomic analysis was conducted to identify plasmid types, virulence factors, and antimicrobial resistance genes, as well as potential resistance mechanisms associated with mutations and plasmid-mediated variants.Results: The isolated hv-CRKP strain exhibited multidrug resistance to carbapenem, tigecycline, and polymyxin. Genomic analysis revealed that the IncHI1B/repB plasmid carried virulence factors (rmpA, ΔrmpA2, iucABCD, iutA), while IncFII/IncR and IncFII plasmids harbored resistance genes [blaCTX-M-65, blaTEM-1B, rmtB, blaSHV-12, blaKPC-2, qnrS1, blaLAP-2, sul2, dfrA14, tet(A), tet(R)]. The coexistence of blaCTX-M-65, blaTEM-1B, blaSHV-12, blaLAP-2,and blaKPC-2 in one hv-CRKP strain is exceptionally rare. Additionally, the Tet(A)-S251A variant in the conjugative plasmid pTET-4 may confer tigecycline resistance. Mutations in MgrB, PhoPQ, and PmrABCDK were identified as potential contributors to increased polymyxin resistance. Interestingly, plasmid-encoded restriction-modification systems and Retron regions were identified, which could potentially confer phage resistance.Discussion: The combination of virulence and antimicrobial resistance factors in the ST11-KL64 hv-CRKP strain represents a significant challenge for treating immunocompromised pediatric patients. Particularly concerning is the resistance to polymyxin and tigecycline, which are often last-resort treatments for multidrug-resistant infections. The findings highlight the urgent need for effective surveillance, infection control measures, and novel therapeutic strategies to manage such hypervirulent and multidrug-resistant pathogens.

1 May 2025 in Nanoscale
Verified
Journal Article
Closed access
PDF file
LSLi Sun
Li Sun
SZSongchen Zhao
Songchen Zhao
SZShishuai Zheng
Shishuai Zheng
LZLei Zhang
Lei Zhang
Jie LinJie Lin
Jie Lin
Aiguo WuAiguo Wu
Aiguo Wu
This review summarizes the latest progress in the field of SERS, including advanced substrate materials and their enhancement mechanisms, with an emphasis on metal cluster-based SERS probes and their biomedical applications.

15 June 2025 in Endocrine
Verified
Journal Article
Closed access
PDF file
QYQingxiang Yu
Qingxiang Yu
WHWeijing Hao
Weijing Hao
YHYanbin He
Yanbin He
XRXianhui Ruan
Xianhui Ruan
LLLin Liu
Lin Liu
XZXiangqian Zheng
Xiangqian Zheng

28 April 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
QYQing-Xiang Yu
Qing-Xiang Yu
WZWen-Jun Zhao
Wen-Jun Zhao
HWHe-Yue Wang
He-Yue Wang
LZLei Zhang
Lei Zhang
LQLan Qin
Lan Qin
JHJian li Han
Jian li Han
NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display promising therapeutic efficacy in NTRK-positive solid tumors. Although some NTRK fusion partners have been identified in thyroid cancer, the spectrum of NTRK fusion is not fully characterized. In this study, a dual NTRK3 fusion was identified by targeted RNA-Seq in a 47-year-old female patient with papillary thyroid carcinoma. The patient harbors a novel in-frame fusion between NTRK3 exon 13 and AJUBA exon 2, co-existing with a known in-frame fusion between ETV6 exon 4 and NTRK3 exon 14. The dual NTRK3 fusion was validated by Sanger sequencing and fluorescence in situ hybridization (FISH) but lack TRK protein expression as defined by pan-TRK immunohistochemistry (IHC). We supposed the pan-TRK IHC result to be falsely negative. In conclusion, we present the first case of a novel NTRK3-AJUBA fusion co-existing with a known ETV6-NTRK3 fusion in thyroid cancer. These findings extend the spectrum of translocation partners in NTRK3 fusion, and the effect of dual NTRK3 fusion on TRK inhibitor therapy and prognosis needs long-term follow-up.

16 August 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
XWXiqian Wang
Xiqian Wang
YLYingao Liu
Yingao Liu
LCLijie Chen
Lijie Chen
JZJie Zhang
Jie Zhang
RJRuoyu Jiang
Ruoyu Jiang
HYHan Yan
Han Yan
Introduction: The prevalence of thyroid nodules and malignancies in the elderly is a growing concern. Thyroid nodules in this population have unique characteristics, requiring careful treatment strategies that balance risks and benefits. Oncocytic carcinoma of the thyroid (OCA) is a rare, aggressive subtype with diagnostic challenges.Methods: This case features an 84-year-old patient who presented with a neck mass and symptoms of asphyxia. Clinical evaluation, imaging studies, and biopsy were conducted to assess the nature of the thyroid lesion. Molecular testing, including genetic analysis, was performed to identify specific mutations associated with OCA and guide treatment decisions.Results: The patient was diagnosed with oncocytic carcinoma of the thyroid. The molecular testing revealed specific genetic mutations indicative of OCA, confirming the diagnosis. The presence of these mutations guided the treatment plan, emphasizing the importance of molecular diagnostics in managing thyroid malignancies, especially in the elderly.Discussion: This case illustrates the complexities of diagnosing and treating thyroid malignancies in the elderly. Biopsy and molecular testing provided diagnostic accuracy and informed treatment. Individualized approaches are essential for better outcomes, especially in aggressive subtypes, balancing the risks and benefits of intervention.